Beyond the hype: Agentic AI takes center stage at HIMSS 2026
Agentic AI transforms healthcare through autonomous agents handling scheduling, documentation and coding at HIMSS 2026. Continue reading →
StockWatch: CytomX Shares Yo-Yo on Colorectal Cancer Data
CytomX Therapeutics (NASDAQ: CTMX) drew attention a few days ago after its six-year-old, up-to-$1.68 billion cancer collaboration with Astellas Pharma (Tokyo: 4503) was terminated by the Japanese pharma giant, but the setback hardly registered with investors of the South San Francisco, CA,...
Novartis Acquires Pikavation for up to $3B, Expanding Cancer Pipeline
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor programs designed to treat forms of cancer. Pikavation’s programs are led by SNV4818, a pan-mutant...1 in 10 ACA enrollees dropped coverage after subsidy lapse: poll
More than half of respondents said their healthcare expenses are “a lot higher” this year, according to the KFF survey. One in 10 reported dropping coverage and becoming uninsured. Continue reading →The post-acute blind spot: Why what happens after discharge matters more than ever
Post-acute care is healthcare’s biggest blind spot — and a major opportunity. Continue reading →Earendil Labs, an AI-powered drugmaker, hauls in $787M
The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi. Continue reading →Roche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study. Continue reading →
David’s Bridal Bets on Indian Brides
CEO Kelly Cook speaks to WWD about their partnership with Kynah to bring South Asian wedding wear into an accessible price range, serving a culturally diverse bride. Continue reading →